Aurobindo Pharma Limited has announced the incorporation of a new wholly owned subsidiary in Indonesia. PT Auro Pharm Indonesia was incorporated on July 1, 2026, with approval received from authorities on July 9, 2026. The company formed the subsidiary through its existing stepdown subsidiary PT Aurogen Pharma Indonesia.
The subsidiary will focus on manufacturing operations in the Indonesian pharmaceutical market. PT Auro Pharm Indonesia operates in the pharmaceuticals industry, with an initial share capital of IDR 20,000,000,000, divided into 2,000 equity shares of IDR 10,000,000 each. The company acquired 100% of the shareholding and control through cash consideration.
Regulatory approvals were not required for this acquisition transaction. The subsidiary structure was established as a stepdown arrangement through PT Aurogen Pharma Indonesia, which is already a wholly owned subsidiary of the company. No governmental or regulatory approvals were required for the formation.
The incorporation represents a strategic expansion of Aurobindo Pharma's manufacturing footprint in Southeast Asia. The new entity is positioned to serve the Indonesian market with locally manufactured pharmaceutical products. in the company's regional growth strategy.
PT Auro Pharm Indonesia's establishment aligns with the company's long-term plans to diversify its geographic presence and expand production capacity. The move follows recent trends of Indian pharmaceutical companies establishing manufacturing bases in strategic international markets.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.